RE:Anyone gonna watch ? REPLICEL LIFE SCIENCES ANNOUNCES MEETING RESULTS
RepliCel Life Sciences Inc. has released the results of its annual general and special meeting of shareholders, held on Thursday, Jan. 16, 2025, in Vancouver. A total of 40,320,914 common shares of the company were represented at the meeting, constituting approximately 54.8 per cent of the total number of common shares of the company issued and outstanding. All matters presented for approval at the meeting were duly authorized and approved.
AGM (annual general meeting) results
Shareholders approved setting the size of the board at three directors, and David Hall and Peter Lewis were re-elected as directors of the company.
Shareholders also approved the appointment of auditor and the renewal of the company's 2013 equity incentive plan.
Special meeting matters
Shareholders approved the proposed asset sale and royalty transaction with 1456390 B.C. Ltd., a company wholly owned by Andrew Schutte, the company's president and chief executive officer. The transaction was approved by special resolution, with 91.65 per cent of the votes cast in favour of the resolution at the meeting, and the requisite majority of minority approval was obtained, in accordance with Multilateral Instrument 61-101, Protection of Minority Security Holders in Special Transactions. The proposed voluntary delisting of the company's shares from the TSX Venture Exchange in connection with the closing of the transaction was also approved, with 90.87 per cent of the votes cast in favour. Such vote excluded the shares held by non-arm's-length parties in accordance with the rules of the TSX Venture Exchange. Closing of the transaction is subject to certain customary closing conditions and the company expects closing of the transaction to occur in the first quarter of 2025. Further updates on the completion of the transaction and delisting will be provided.